Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study

被引：0
|
作者：
Pla-Juher, Helena [1 ,2 ,4 ]
Pardo, Marta [2 ]
Izquierdo, Angel J. [2 ,3 ,4 ]
Darder, Esther [3 ,4 ]
Carbo, Anna [1 ,2 ,4 ]
Munte, Elisabet [5 ]
Torres-Esquius, Sara [6 ]
Balmana, Judith [6 ]
Lazaro, Concepcion [5 ,7 ]
Brunet, Joan M. [1 ,2 ,3 ,4 ]
Barretina-Ginesta, Maria-Pilar [1 ,2 ,4 ]
机构：
[1] Hosp Univ Dr Josep Trueta, Catalan Inst Oncol, Med Oncol, Avinguda Franca S-N, Girona 17707, Spain
[2] Inst Invest Biomed Girona IDIBGI, Precis Oncol Grp OncoGIR Pro, Girona, Spain
[3] IDIBGI, Catalan Inst Oncol, Hereditary Canc Program, Girona, Spain
[4] Dept Epidemiol & Canc Register, Girona, Spain
[5] IDIBELL, Catalan Inst Oncol, Hereditary Canc Program, Barcelona, Spain
[6] Vall dHebron Hosp, Dept Med Oncol, Barcelona, Spain
[7] Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
来源：
CLINICAL & TRANSLATIONAL ONCOLOGY | 2024年 / 26卷 / 04期
关键词：
Endometrial cancer; Breast cancer; Risk-reducing salpingo-oophorectomy; BRCA; Mutation; Hysterectomy; Tamoxifen; Carcinosarcoma; Serous carcinoma; Endometrioid carcinoma; REDUCING SALPINGO-OOPHORECTOMY; UTERINE SEROUS CARCINOMA; BRCA2; MUTATIONS; BREAST-CANCER; WOMEN; HYSTERECTOMY; METAANALYSIS; SURGERY; TIME;
D O I：
10.1007/s12094-023-03312-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objective To know the risk of endometrial cancer (EC) in a population of women with BRCA 1/2 pathogenic or likely pathogenic variants after risk-reducing salpingo-oophorectomy (RRSO).Methods The study cohort included data from 857 women with BRCA mutations who underwent RRSO visited four hospitals in Catalonia, Spain, from January 1, 1999 to April 30, 2019. Standardized incidence ratio (SIR) of EC was calculated in these patients using data from a regional population-based cancer registry.Results After RRSO, eight cases of EC were identified. Four in BRCA 1 carriers and four in BRCA2 carriers. The expected number of cases of EC was 3.67 cases, with a SIR of 2.18 and a 95% CI (0.93-3.95).Conclusions In our cohort, the risk of EC in BRCA1/2 carriers after RRSO is not greater than expected. Hysterectomy is not routinely recommended for these patients.
引用
收藏
页码：1033 / 1037
页数：5
相关论文
共 50 条
  • [1] Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study
    Helena Pla-Juher
    Marta Pardo
    Àngel J. Izquierdo
    Esther Darder
    Anna Carbó
    Elisabet Munté
    Sara Torres-Esquius
    Judith Balmaña
    Concepción Lázaro
    Joan M. Brunet
    Maria-Pilar Barretina-Ginesta
    Clinical and Translational Oncology, 2024, 26 : 1033 - 1037
  • [2] BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study
    Kitson, Sarah J.
    Bafligil, Cemsel
    Ryan, Neil A. J.
    Lalloo, Fiona
    Woodward, Emma R.
    Clayton, Richard D.
    Edmondson, Richard J.
    Bolton, James
    Crosbie, Emma J.
    Evans, D. Gareth
    EUROPEAN JOURNAL OF CANCER, 2020, 136 : 169 - 175
  • [3] Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers
    Lee, Y. C.
    Milne, R. L.
    Lheureux, S.
    Friedlander, M.
    McLachlan, S. A.
    Martin, K. L.
    Bernardini, M. Q.
    Smith, C.
    Picken, S.
    Nesci, S.
    Hopper, J. L.
    Phillips, K. A.
    EUROPEAN JOURNAL OF CANCER, 2017, 84 : 114 - 120
  • [4] Incidence of endometrial cancer in BRCA mutation carriers
    Kotsopoulos, Joanne
    Lubinski, Jan
    Huzarski, Tomasz
    Bychkovsky, Brittany L.
    Moller, Pal
    Kim, Raymond H.
    Tung, Nadine
    Eisen, Andrea
    Foulkes, William
    Singer, Christian F.
    Aeilts, Amber
    Neuhausen, Susan L.
    Bordeleau, Louise
    Karlan, Beth
    Fruscio, Robert
    Eng, Charis
    Olopade, Olufunmilayo
    Zakalik, Dana
    Couch, Fergus
    Cajal, Teresa Ramon y
    Sun, Ping
    Gronwald, Jacek
    Narod, Steven A.
    GYNECOLOGIC ONCOLOGY, 2024, 189 : 148 - 155
  • [5] Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers
    Mavaddat, Nasim
    Antoniou, Antonis C.
    Mooij, Thea M.
    Hooning, Maartje J.
    Heemskerk-Gerritsen, Bernadette A.
    Nogues, Catherine
    Laborde, Lilian
    Breysse, Emmanuel
    Stoppa-Lyonnet, Dominique
    Gauthier-Villars, Marion
    Buecher, Bruno
    Caron, Olivier
    Fourme-Mouret, Emmanuelle
    Fricker, Jean-Pierre
    Lasset, Christine
    Bonadona, Valerie
    Berthet, Pascaline
    Faivre, Laurence
    Luporsi, Elisabeth
    Mari, Veronique
    Gladieff, Laurence
    Gesta, Paul
    Sobol, Hagay
    Eisinger, Francois
    Nogues, Catherine
    Longy, Michel
    Dugast, Catherine
    Colas, Chrystelle
    Coupier, Isabelle
    Pujol, Pascal
    Corsini, Carole
    Lortholary, Alain
    Vennin, Philippe
    Adenis, Claude
    Nguyen, Tan Dat
    Delnatte, Capucine
    Tinat, Julie
    Tennevet, Isabelle
    Limacher, Jean-Marc
    Maugard, Christine
    Bignon, Yves-Jean
    Demange, Liliane
    Penet, Clotilde
    Dreyfus, Helene
    Cohen-Haguenauer, Odile
    Venat-Bouvet, Laurence
    Leroux, Dominique
    Zattara-Cannoni, Helene
    Fert-Ferrer, Sandra
    Bera, Odile
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [6] Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis
    Marchetti, C.
    De Felice, F.
    Boccia, S.
    Sassu, C.
    Di Donato, V.
    Perniola, G.
    Palaia, I.
    Monti, M.
    Muzii, L.
    Tombolini, V.
    Panici, P. Benedetti
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 132 : 111 - 115
  • [7] The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: An international prospective cohort study
    Segev, Yakir
    Iqbal, Javaid
    Lubinski, Jan
    Gronwald, Jacek
    Lynch, Henry T.
    Moller, Pal
    Ghadirian, Parviz
    Rosen, Barry
    Tung, Nadine
    Kim-Sing, Charmaine
    Foulkes, William D.
    Neuhausen, Susan L.
    Senter, Leigha
    Singer, Christian F.
    Karlan, Beth
    Ping, Sun
    Narod, Steven A.
    GYNECOLOGIC ONCOLOGY, 2013, 130 (01) : 127 - 131
  • [8] Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers
    Lee, Young-Jae
    Lee, Shin-Wha
    Kim, Kyu-Rae
    Jung, Kyung-Hae
    Lee, Jong-Won
    Kim, Yong-Man
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2017, 28 (01)
  • [9] The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers Implications for Counseling
    Vencken, Peggy M. L. H.
    Kriege, Mieke
    Hooning, Maartje
    Menke-Pluymers, Marian B.
    Heemskerk-Gerritsen, Bernadette A. M.
    van Doorn, Lena C.
    Collee, Margriet M.
    Jager, Agnes
    van Montfort, Cees
    Burger, Curt W.
    Seynaeve, Caroline
    CANCER, 2013, 119 (05) : 955 - 962
  • [10] Risk Management for BRCA1/BRCA2 Mutation Carriers Without and With Breast Cancer
    Mainor, C. B.
    Isaacs, C.
    CURRENT BREAST CANCER REPORTS, 2020, 12 (02) : 66 - 74
12345